Dishman Carbogen Amcis Ltd
NSE:DCAL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
DCAL's latest stock split occurred on May 2, 2016
The company executed a 2-for-1 stock split, meaning that for every share held, investors received 2 new shares.
The adjusted shares began trading on May 2, 2016. This was DCAL's 2nd stock split, following the previous one in Oct 21, 2005.
Global
Stock Splits Monitor
| Date | Company | Split | Pre-Split Price | Post-Split Price | |
|---|---|---|---|---|---|
|
Apr 23, 2026
|
|
Red Sky Energy Ltd
ASX:ROG
|
5-for-4
x1.25
|
0.002 0.0016 AUD | 0.002 0.002 AUD |
|
Apr 23, 2026
|
J
|
Jiusheng Electric Co Ltd
SZSE:301082
|
1-for-1
x1
|
17.33 13.2508 CNY | 12.9 12.9 CNY |
|
Apr 23, 2026
|
S
|
Saudee Group Bhd
KLSE:SAUDEE
|
1-for-10
/10
|
0.01 0.1 MYR | 0.09 0.09 MYR |
|
Apr 23, 2026
|
|
Focus Technology Co Ltd
SZSE:002315
|
1-for-1
x1
|
44.3999 33.4538 CNY | 32 32 CNY |
|
Apr 22, 2026
|
S
|
Sharetronic Data Technology Co Ltd
SZSE:300857
|
1-for-1
x1
|
304.5701 217.2101 CNY | 260.76 260.76 CNY |
ROG
002315
Dishman Carbogen Amcis Ltd
Glance View
Dishman Carbogen Amcis Ltd. is a manufacturing company, which engages in the provision of outsourcing services for the pharmaceutical industry. The company is headquartered in Ahmedabad, Gujarat. The company went IPO on 2017-09-21. The firm's segments include CRAMS and Vitamin - D, Bulk Drugs, Quats, Specialty Chemicals and traded goods. The firm assists pharma companies through various stages of drug development from process research and development to late-stage clinical and commercial manufacturing facilities, along with the supply of active pharmaceutical ingredients (APIs) and intermediates. The firm has manufacturing and research facilities in India, Switzerland, France, Netherlands, United Kingdom and China. The firm's subsidiaries include CARBOGEN AMCIS (Shanghai) Co. Ltd, Dishman Infrastructure Ltd., Dishman Carbogen Amcis (Singapore) Pte. Ltd., CARBOGEN AMCIS Holding AG and Dishman Biotech Ltd.
